PULSE BIOSCIENCES, INC. — Director's Dealing 2022

Jun 11, 2022

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: Pulse Biosciences, Inc. (PLSE)
CIK: 0001625101
Period of Report: 2022-06-09

Reporting Person: Zanganeh Maky (Director)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2022-06-09	Common Stock	X	86668	—	Acquired	442168	Direct

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2022-06-09	Warrant (right to buy)	$2.05	P	86668	Acquired	2027-06-09	Common Stock (86668)	Direct

Holdings (Non-Derivative)

Security	Shares	Ownership
Common Stock	27000	Indirect
Common Stock	14000	Indirect
Common Stock	107074	Indirect

Footnotes

F1: The Reporting Person acquired the shares of common stock and the warrants pursuant to the exercise of subscription rights in connection with the Issuer's previously announced rights offering (the "Rights Offering"), as disclosed in the Registration Statement on Form S-3, as amended, and the Prospectus Supplement and certain Current Reports on Form 8-K filed by the Issuer with the SEC.

F2: Pursuant to the terms of the Rights Offering, the Reporting Person purchased units at a price of $2.05 per unit, with each unit consisting of one share of common stock and a warrant to purchase one share of common stock at an exercise price of $2.05.